Division of Gastroenterology, Department of Internal Medicine, Buddhist Tzu Chi General Hospital, Taipei Branch, Taiwan.
Expert Rev Gastroenterol Hepatol. 2012 Aug;6(4):497-506. doi: 10.1586/egh.12.24.
In 2009, several different research groups simultaneously identified the polymorphisms close to IL28B gene as an important predictor of therapeutic response for chronic hepatitis C (CHC) patients receiving interferon-based treatment using approaches of genome-wide association studies. They also found that these genetic variations were strongly associated with the spontaneous viral clearance of hepatitis C virus (HCV) infection. Following these studies, ITPA gene variants were reported to affect ribavirin-induced anemia and therapeutic outcomes of CHC patients. All these lines of evidence usher in a new genomic era for the management of HCV infection. In this article, advances in recent genome-wide association studies regarding HCV infection, and their impacts on the management of CHC patients will be reviewed. In addition, the clinical usefulness of genomic variations on the addition of direct antiviral agents to current standard of care will be discussed.
2009 年，几个不同的研究小组同时通过全基因组关联研究方法发现，IL28B 基因附近的多态性是接受基于干扰素治疗的慢性丙型肝炎（CHC）患者治疗反应的重要预测因子。他们还发现这些遗传变异与丙型肝炎病毒（HCV）感染的自发性病毒清除密切相关。在这些研究之后，ITPA 基因变异被报道会影响利巴韦林诱导的贫血和 CHC 患者的治疗结果。所有这些证据都为 HCV 感染的管理带来了一个新的基因组时代。本文将综述 HCV 感染的全基因组关联研究的最新进展及其对 CHC 患者管理的影响。此外，还将讨论在现有标准治疗基础上添加直接抗病毒药物时基因组变异的临床应用价值。
